A daily pill designed to target pancreatic cancer has demonstrated promising results in its first human trial. Daraxonrasib, developed to block cancer signals linked to the RAS gene, completed an early-stage clinical study involving 168 patients with advanced disease. All participants had previously undergone at least one chemotherapy treatment before enrolling in the research. The trial evaluated both safety and effectiveness of the medication in patients whose tumors carried RAS gene mutations.
The study was conducted at the Dana-Farber Cancer Institute and published in The New England Journal of Medicine. Researchers focused on patients with metastatic pancreatic cancer who had exhausted initial treatment options. The drug’s mechanism targets multiple active cancer signals that fuel tumor cell growth, a critical approach given that more than 90% of pancreatic cancers carry these harmful genetic alterations.
Drug blocks multiple cancer pathways unlike existing treatments
Daraxonrasib differs from older medications that target RAS mutations. Previous drugs only worked on specific mutation types that are uncommon in pancreatic cancer, such as certain KRAS variations. The new pill operates as a multi-selective inhibitor, meaning it can block several cancer-driving pathways simultaneously. This broader approach addresses the genetic profile found in nearly all pancreatic cancer cases.
At the 300-milligram dose—the amount planned for larger phase 3 trials—approximately 30% of patients experienced a positive response. More significantly, about 90% of participants had their cancer either shrink or stop progressing. These outcomes represent a substantial improvement over historical results with chemotherapy in previously treated patients. The drug maintained disease control in the vast majority of cases, a rate rarely seen in this aggressive cancer type.
Side effects manageable with supportive care measures
The trial documented several side effects among participants. The most common adverse reactions included:
- Skin rash affecting multiple patients
- Mouth inflammation requiring management
- Nausea experienced during treatment
- Diarrhea in varying severity
Despite these reactions, most patients tolerated the treatment with supportive care interventions. Very few participants needed to discontinue therapy due to side effects. Researchers noted that standard medical management techniques effectively controlled most adverse symptoms, allowing patients to continue treatment without significant interruption.
Research team sees potential for treatment paradigm shift
Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber, described the development as potentially transformative. He emphasized that if future clinical trials support these initial findings, daraxonrasib would become a targeted therapy relevant to nearly all patients with advanced pancreatic cancer. The trial provided the first published data showing the safety and broad activity of a RAS multi-selective inhibitor in this disease.
Wolpin characterized the drug as one of the most promising therapy advances seen in pancreatic cancer, a disease that has historically had very few effective treatments. The 90% disease control rate in metastatic pancreatic cancer patients particularly excited researchers. This level of response exceeds what has been observed in prior clinical trials of chemotherapy for previously treated patients with metastatic disease.
Study limitations require larger trials for confirmation
As a phase 1/2 study, this research does not definitively prove daraxonrasib’s superiority compared to standard chemotherapy. The trial did not include a randomized control arm that directly compared the new drug with conventional treatment. However, the results appeared substantially better than historical data from chemotherapy trials in similar patient populations.
Additional questions remain about how the drug may perform earlier in the disease course. The trial included only patients who had already received prior treatments, leaving uncertainty about its effectiveness as a first-line therapy. Future studies will need to determine optimal timing and whether combining daraxonrasib with other treatments could produce more durable responses.
Independent expert anticipates breakthrough presentation at medical conference
Dr. Brian Slomovitz, director of gynecologic oncology at Mount Sinai Medical Center in Miami Beach, expressed enthusiasm about the development. He noted that greater than 90% of pancreatic cancers have activation of KRAS, a major factor in cancer development and progression. The upcoming presentation of full dataset results at a major oncology conference will provide more comprehensive information about the drug’s performance.
Slomovitz suggested that doubling survival time in pretreated patients would be unprecedented if confirmed by the complete dataset. He described the potential magnitude of benefit as capable of reshaping the treatment landscape and establishing a new standard of care. While emphasizing the need to evaluate full data for both efficacy and safety, the expert expressed genuine optimism for patients and families affected by this challenging disease. The research represents real momentum toward effective treatments, though investigators stress the drug remains investigational and is not a cure. Additional research continues to determine how best to sequence or combine therapies to provide the most durable clinical outcomes for pancreatic cancer patients.